Lonza to Acquire Merck KGaA's US CDMO Assets for ~CHF 100–700M, North American Sites 4 to 9
On November 3, Lonza signed a definitive agreement to acquire Merck KGaA's five US CDMO manufacturing sites and related businesses for a low-to-mid triple-digit-million Swiss francs enterprise value (market estimates from about CHF 120M). About 1,100 employees transfer with the assets; closing is expected mid-2027. The deal doubles Lonza's US CDMO footprint from 4 to 9 sites.
On November 3 (Basel time), Lonza announced a definitive agreement to acquire Merck KGaA's five US CDMO manufacturing sites and associated businesses, with about 1,100 employees transferring with the assets. The transaction is an all-cash deal expected to close in mid-2027, subject to regulatory approval. Lonza's US CDMO base grows from 4 to 9 sites, with its US headcount exceeding 6,000.
A clarification on names: the seller is Merck KGaA (Darmstadt, Germany) — the life-science reagents, consumables and testing giant — not Merck & Co. (known as MSD outside the US). The two are frequently conflated; in this deal, Merck KGaA is divesting heavy-asset contract manufacturing to refocus on its upstream life-science portfolio.
The asset package is a precise ADC / cell-and-gene / advanced-delivery map. It includes the former Exelead ADC conjugation plant in St. Louis (bioconjugation); Madison and Verona, Wisconsin (high-potency payload-linkers); Carlsbad, California (viral vectors and sterile fill-finish); and Indianapolis (LNP, liposomes, PEGylated proteins). Merck's BioReliance testing business is not part of the sale.
Strategically, the deal fills Lonza's North American gaps in ADC, CGT and advanced delivery — squarely aligned with its 'One Lonza' strategy of concentrating on advantaged modalities. Lonza expects the package to contribute about CHF 250M of revenue in 2028, with near-term CORE EBITDA margin below the group average and a target to lift it to group level by the mid-2030s. Funding comes from existing cash and credit facilities and does not affect Lonza's BBB+ rating. For Merck KGaA, it is another step in shedding non-core manufacturing to focus on upstream life-science reagents, consumables and testing.
The move fits a broader Western-CDMO 'buy capacity' wave rather than a retreat. In the same week, Cambrex broke ground on a USD 120M Iowa expansion adding 160,000 L (raising total capacity nearly 25% to almost 1M L), and AGC Biologics expanded a EUR 500M-plus agreement across Copenhagen and Japan. Global CDMO players are still concentrating capacity around new modalities — ADC, CGT and delivery — even as legacy, non-core assets are shed. For Chinese CXDMO players, this arms race around new-modality capacity and global localization is both the flip side of order competition and a window to rewrite the differentiation moat.